Targeting for success: mechanistic insights into microRNA-based gene therapy for Huntington disease

Sogorb Gonzalez, M.

Chapter 1

Targeting for success:
Mechanistic insights into HTT–lowering therapies for Huntington disease

Marina Sogorb-Gonzalez[1,2], Pavlina Konstantinova[2], Sander van Deventer[1,2]

[1] Department of Gastroenterology and Hepatology, Leiden University Medical Center, The Netherlands

[2] Department of Research, VectorY B.V, Amsterdam, The Netherlands

1

Abstract

Gene therapy is emerging as a potential treatment for untreatable neurodegenerative diseases. Huntington Disease (HD) is the most common inherited neurogenerative disease caused by a trinucleotide repeat expansion in the huntingtin (HTT) gene, giving rise to a toxic mutant HTT (mHTT) protein. The well-defined monogenic cause makes HD a good target for gene therapy approaches and several novel therapeutics are being developed with the aim of reducing the production of the mHTT. In view of recent failures of some therapeutics to translate into patient benefit, it is essential to precisely understand the pathogenic mechanisms that are currently targeted as well as the mechanism of action of the HTT-lowering therapies in development. We here review our current understanding of the molecular pathology of HD, how to specifically target the critical pathogenic mechanisms and how to determine therapeutic efficacy. Finally, we discuss the current challenges for HTT-lowering therapies and the ongoing advances of gene therapy treatments to overcome these therapeutic limitations.

Introduction

Huntington Disease (HD) is an ultimately lethal, genetic neurodegenerative disease that typically manifests in adulthood with motor, cognitive and psychological symptoms. Symptomatic onset is characterized by the appearance of chorea and muscle rigidity, often preceded or accompanied by neuropsychiatric symptoms like depressed mood, mania, irritability and psychosis (Ross *et al.*, 2014). HD is dominantly inherited and is the most common genetic disease affecting the central nervous system (CNS) with a prevalence of 1 to 9 in 100.000 people, depending on the ethnicity and population (Rawlins *et al.*, 2016). Symptomatic therapies are used to treat motor and psychological symptoms and may have a temporary beneficial effect on motor function and quality of life (Bachoud-Lévi *et al.*, 2019). Unfortunately, despite decades of research and ongoing clinical trials, there is still no established treatment to attenuate the natural course of this devastating disease.

HD is caused by a trinucleotide CAG repeat expansion in exon 1 of the huntingtin (*HTT*) gene (MacDonald *et al.*, 1993). Individuals who inherit ≥ 40 CAG repeats will develop HD given a normal lifespan, with longer repeats resulting in earlier age of onset. Expansions with 36-39 CAG repeats are considered alleles with reduced penetrance. The expanded CAG repeat sequence results in the transcription of a mutant form of huntingtin protein (mHTT) containing an expanded polyglutamine (polyQ) tract in the N-terminal domain. This long polyglutamine tract confers a toxic gain-of-function to the mHTT protein which has been associated with neuronal dysfunction mechanisms including transcriptional dysregulation, proteasome overload, excitotoxicity, mitochondria and synaptic dysfunction, and eventually, cell death (Jimenez-Sanchez *et al.*, 2017; Tabrizi *et al.*, 2020).

The fact that mHTT is expressed since birth and in all tissues, but only becomes pathological in adulthood and initially in striatal neurons, raises the question whether mHTT, or other potentially related mechanisms, are the main driver of HD pathology (Jimenez-Sanchez *et al.*, 2017). Moreover, the CAG length-dependent age of onset also suggests that the relationship between mHTT protein and HD pathogenesis might be more complex. These considerations have become relevant in view of the recent finding that therapies exclusively reducing the mHTT protein have not achieved the expected therapeutic benefits (Kingwell, 2021).

Hence, understanding the different mechanistic aspects of HD pathology and disease-modifying approaches will forward the development of successful therapies. In this chapter, we introduce the current knowledge in the field, as well as therapeutic limitations related to HD pathology, drug modalities and measurements of efficacy, with special focus on HTT-lowering therapies. For this, the field has been categorized into the following questions (**Figure 1**):

- ***WHAT?***: Which pathological mechanisms contribute to HD and what is the most promising target to stop neurodegeneration and HD progression?
- ***HOW?***: Which currently available technologies are the most suitable to target these mechanisms?
- ***WHERE?***: Which brain regions do we need to target to achieve significant therapeutic effect and which technologies can accomplish this?
- ***HOW GOOD?***: Which models and outcomes are used to measure efficacy for successful translation to patients? Which new markers should be developed for gene therapy studies?
- ***HOW BAD?***: What are the toxicities and immunogenic responses associated with the treatment?


Figure 1: Important questions to investigate the disease pathology and potential targets, properties of current drug modalities, and outcomes of efficacy and safety with the goal to develop successful therapies for HD and other neurodegenerative diseases.

WHAT? – Pathological molecular mechanisms in HD

Despite its monogenic cause, HD pathology is not fully understood and curative therapies are not yet available. A better understanding of the pathological mechanisms leading to the gradual loss of striatal neurons and the midlife onset of symptoms will enable the development of novel therapeutic approaches.

Initially, it was generally accepted that the expression and aggregation of mHTT was the direct toxic molecular driver of HD pathogenesis and early studies in post-mortem patients identified mHTT inclusions in the striatum and cortex as the pathological hallmark of HD (DiFiglia, 1997). At the same time, the first genetic mouse models demonstrated that the incorporation of a long CAG expansion in *HTT* homologous mouse gene or the expression of mHTT cDNA sequences also led to mHTT inclusions, neuronal death and HD-like phonotype in mice (Mangiarini *et al.*, 1996; Menalled *et al.*, 2002). These studies supported the toxic gain-of function of mHTT and the hypothesis that the prevention of mHTT aggregate formation should be a promising therapeutic strategy for treatment of HD. During the last therapies (Wild and Tabrizi, 2017, Tabrizi *et al.*, 2019*a*; Marxreiter *et al.*,

2020). However, the lack of efficacy of some of such approaches raised concerns about the notion that mHTT constitutes a valid therapeutic target (Kingwell, 2021).

The CAG repeat expansion does have consequences for neuronal biology that extend beyond the production of mHTT aggregates (Tabrizi *et al.*, 2020; Heinz *et al.*, 2021). These include somatic DNA repeat instability, formation of aberrant spliced toxic transcripts and nuclear RNA foci, sequestration of proteins involved in transcriptional regulation and impairment of proteasome function, among others. Recent research has investigated the contribution of these processes as potential drivers of the striatum-selective and age-dependent pathogenesis.

The expanded CAG repeat is unstable and undergoes a progressive increase in length throughout patient's life, process known as somatic instability (Swami *et al.*, 2009). Somatic instability occurs in a tissue-specific manner in HD patients, with striatal neurons undergoing a dramatic mutation length increase up to >1000 CAG repeats (Kennedy *et al.*, 2003). A novel mouse model of somatic instability with uninterrupted CAG repeats (BAC-CAG model) showed significant correlations between somatic instability in the striatum and nuclear mHTT aggregation with the onset of behavioral impairments and other molecular phenotypes (transcriptomic dysregulation and reactive gliosis) which closely resemble HD clinical pathology (Gu *et al.*, 2022). In addition, GWAS studies identified genes involved in DNA mismatch repair (MMR) as contributors of somatic instability disease and worse HD outcomes in HD patients (Lee *et al.*, 2015; Ciosi *et al.*, 2019; Roy *et al.*, 2021). Altogether, these studies support the hypothesis that somatic instability, leading to CAG repeat expansions greatly exceeding the germ-line number, contributes to the onset and progression of striatum-selective pathology in HD.

Not all mHTT protein species are equally pathogenic, and increased somatic CAG expansion in striatal neurons is considered to contribute to the production of the highly toxic exon 1 HTT (HTTex1) fragment through aberrant splicing. Mutant *HTT* pre-mRNA undergoes incomplete splicing of exon1 to exon 2 resulting in the production of a short HTTex1 protein (Sathasivam *et al.*, 2013). Furthermore, in an HD patient's tissue, this mis-spliced HTT transcript can be detected (Neueder *et al.*, 2017). The severe toxicity induced by HTTex1 has been demonstrated in different HD animal models and indeed the fastest progressing HD mouse model is based on the overexpression of HTTex1 fragment (Mangiarini *et al.*, 1996; Barbaro *et al.*, 2015). Phenotype onset correlates with levels of HTTex1 splicing in mouse models with similar CAG repeats (Franich *et al.*, 2019). Importantly, the suppression of HTTex1 expression in a conditional model was able to reverse aggregate formation and motor decline (Yamamoto *et al.*, 2000), suggesting that HTTex1 reduction is beneficial for therapeutic efficacy in HD. Longer CAG repeats correlate with increased aberrant splicing and HTTex1 levels (Neueder *et al.*, 2018) and therefore

toxic HTTex1 formation is expected to occur first in neurons that display somatic expansions, such as striatal neurons (Kennedy *et al.*, 2003). For these reasons, it is currently thought that lowering levels of HTTex1 protein will have a greater therapeutic benefit than exclusively targeting the full-length mHTT. Unfortunately, most of the current therapies in preclinical and clinical studies are based on genetic approaches that target sequences downstream exon 1 and therefore are not expected to reduce the translation of the HTTex1 protein.

In conclusion, novel molecular findings, such us somatic instability, CAG repeat expansions and increased generation of toxic HTTex1 fragments, open the door to new therapeutic approaches in HD. In particular, HD pathogenesis is now thought to be a two-step event (presumably including CAG length expansions and HTTex1 production) rather than a result of direct full-length mHTT-induced toxicity (Neueder *et al.*, 2017). According to this model, somatic CAG repeat instability that first accumulates in striatal neurons during the patient's pre-symptomatic years, and not the congenital number of CAG repeats, would trigger the formation of toxic drivers, such as HTTex1, up to a cell type-specific lethal threshold that results in the neurodegeneration of vulnerable cells and disease manifestation(Neueder *et al.*, 2017; Pinto *et al.*, 2020) **(Figure 2).** Consequently, therapies that stop somatic instability or reduce the levels of toxic HTTex1 fragments, ideally in striatal neurons in early disease state, may be potential treatments for HD patients.

**Figure 2: Two-step model of HD pathogenesis.** Based on this model CAG expansions, which increase via somatic instability (step 1), induce and accelerate the formation of the pathogenic HTTex1 fragment by aberrant splicing (step 2) up to a threshold level in which induces neuronal dysfunction and cell death during pre-symptomatic phase. Dotted lines represent the "threshold level" that induces the next process.

HOW? - HTT-targeting therapeutic modalities

As a consequence of a better understanding of HD pathology, current therapeutic approaches have shifted from symptomatic to molecular disease-modifying treatments. With the aim to reduce mHTT-induced toxicity, molecular treatments have been used to edit, silence or reduce mHTT expression and protein translation (Tabrizi *et al.*, 2019*a*; Leavitt *et al.*, 2020; Marxreiter *et al.*, 2020). The efficacy of each of this HTT-lowering approaches would mainly depend on where the intervention targets the HTT pathway: DNA, RNA or protein (Wild and Tabrizi, 2017). The most advanced HTT-targeting therapies are illustrated in **Table 1**.

- DNA-targeting treatments: DNA-targeting therapeutics would be ideal to address all aspects of CAG-induced toxicities. Although challenging, these technologies aim at either removing the mutated gene or inhibiting the transcription. The two technologies in development include zinc finger protein (ZFP) and the novel CRISPR-Cas9 (Yang *et al.*, 2017; Zeitler *et al.*, 2019). Both approaches are gene therapy products mediated by the expression of therapeutic proteins delivered by viral vectors.

- RNA-targeting treatments: RNA-targeting approaches are the only genetic therapies that have been tested in clinical trials to date. These treatments aim at inducing *mHTT* mRNA degradation, consequently resulting in reduction of mHTT protein and aggregates. Three molecular therapeutics have been used: antisense oligonucleotides (ASO) (Carroll *et al.*, 2011; Kordasiewicz *et al.*, 2012, Tabrizi *et al.*, 2019*a*), RNAi interference molecules (microRNA (miRNA), small interfering RNA (siRNA) and short hairpin RNA (shRNA)) (Rodriguez-Lebron *et al.*, 2005; McBride *et al.*, 2011; Miniarikova *et al.*, 2016; Alterman *et al.*, 2019), and small molecules (Bhattacharyya *et al.*, 2021). The various approaches importantly differ in their therapeutic efficacy, CNS target area coverage and durability. Importantly, and often overlooked, is the fact that the mRNA target sequence critically determines the lowering of aberrantly-spliced mHTT transcripts, such as HTTex1 (Sathasivam *et al.*, 2013). Therapies targeting sequences downstream of exon 1 will generally not affect the production of HTTex1, despite lowering the full-length mHTT protein.

- Protein-targeting modalities: These include the direct targeting of mHTT with intracellular antibodies (Southwell *et al.*, 2009), the modulation of degradation pathways such as autophagy and proteasome (Soares *et al.*, 2019), and the inhibition of proteolytic cleavage to reduce toxic N-terminal fragments (except for HTTex1 fragment) (Wellington *et al.*, 2000).

Table 1: Most advanced HTT-targeting therapies for HD.

Sponsor	Drug name	Clinical status	WHAT? (Target)	HOW?	WHERE? (injection route)	Reference
ASO & siRNA						
Ionis/Roche	Tominersen /RO7234292	Phase 1b/2 Phase 3 – *Suspended – lack of efficacy*	RNA (Target: *HTT* exon 36)	ASO	Intrathecal	(Kordasiewicz *et al.*, 2012, Tabrizi *et al.*, 2019) **NCT03761849**
Wave Life Sciences	WVE-120101 WVE-120102	Phase 1b/2a- *Suspended – lack of efficacy*	RNA (Target: mHTT SNP)	ASO	Intrathecal	**NCT04617847** **NCT04617860**
	WVE-003	Phase 1b-2a- recruiting	RNA (Target: mHTT SNP)	ASO	Intrathecal	**NCT05032196**
Alnylam	ALN-HTT	Preclinical	RNA (Target: *HTT* exon 1)	siRNA (cholesterol-conjugated)	Intraparenchymal	(DiFiglia *et al.*, 2007)
Atalanta		Preclinical	RNA (Target: 3' UTR)	siRNA (divalent-siRNA)	Intrastriatal	(Alterman *et al.*, 2019)
Biomarin/Vico		Preclinical	RNA (Target: CAG repeat)	ASO		(Datson *et al.*, 2017)
Nanjing University, China		Preclinical	RNA (Target: *HTT* exon 1)	Exosome-mediated siRNA	Intravenous	(Wu *et al.*, 2018)

Continuation Table 1

Sponsor	Drug name	Clinical status	WHAT? (Target)	HOW?	WHERE? (injection route)	Reference
Gene therapy approaches (ZFP, CRISPR and miRNA)						
Takeda/ Sangamo	TAK-686	Preclinical	DNA – CAG repeat	AAV-ZFP	Intraparenchymal	(Zeitler et al., 2019)
Imperial college London		Preclinical	DNA – CAG repeat	AAV-ZFP	Intraparenchymal (striatum)	(Garriga-Canut et al., 2012)
Emory university		Preclinical	DNA – CAG repeat	AAV-CRISPR/Cas9	Intraparenchymal	(Yang et al., 2017)
uniQure	AMT-130 (AAV-miHTT)	Phase 1b/2 - *Ongoing*	RNA (Target: *HTT* exon 1)	AAV5-miRNA (pre-miR-451)	Intraparenchymal (striatum)	(Miniarikova et al., 2016) **NCT04120493**
Voyager	VY-HTT01	Phase 1b – *Recruiting*	RNA (Target: *HTT* exon 2)	AAV1-miRNA (pre-miR-30)	Intraparenchymal Putamen-thalamus	(Stanek et al., 2014) **NCT04885114**
Spark		*Preclinical*	RNA (Target: *HTT* exon 52)	AAV1-miRNA (pre-miR-30)	Intraparenchymal: Putamen	(McBride et al., 2011)
University of Massachusetts		Preclinical	RNA (Target: *HTT* exon 48)	AAV9-miRNA (pre-miR-155)	Intraparenchymal (Striatum and cortex)	(Pfister et al., 2017)
Small molecules						
PTC therapeutics	PTC518	Preclinical	RNA - Splicing modulator	Small molecule	Oral	Bhattacharyya et al. abstract at HSG 2021
Novartis	Branaplam	Phase 1	RNA – Splicing modulator	Small molecule	Oral	(Keller et al., 2022)
Others						
Triplet therapeutics	TTX-3360	Preclinical/IND	*MSH3* gene (DNA damage repair)	ASO	Intracerebroventricular (ICV)	Antonijevic et al. presentation at EHDN 2021 meeting

1

Gene therapy for HD

Gene therapy was proposed as a therapeutic tool 30 years ago to deliver genetic material to cells with the aim to alter gene expression (Friedmann, 1992). The DNA material is delivered using a carrier (vector), most commonly based on an adeno-associated virus (AAV), and is then transcribed utilizing the cell's own machinery resulting in continuous expression of the therapeutic transgene. Depending on the nature of the transgene, gene therapy can be used to correct defective genes by introducing a functional copy, to silence mutant alleles using RNAi or to deliver gene-editing technologies (Piguet *et al.*, 2017; Papanikolaou and Bosio, 2021). In HD, the molecular therapeutics tested in a gene therapy modality include the expression of HTT-targeting miRNAs and shRNAs (Rodriguez-Lebron *et al.*, 2005; Miniarikova *et al.*, 2016), CAG-targeting ZFP and CRISPR-Cas9 molecules (Yang *et al.*, 2017; Zeitler *et al.*, 2019), and mHTT-targeting intrabodies (Southwell *et al.*, 2009). The main advantage of gene therapy for brain diseases is that a single administration in affected brain areas, although invasive, can potentially result in long-term correction of disease pathology and lifelong treatment.

WHERE? - Therapeutic coverage of affected brain areas in HD

A basic principle in drug development is that the therapeutic drug should distribute to the diseased target tissues. HD pathology is characterized by intranuclear and cytoplasmic insoluble aggregates of mHTT in neuronal cells (DiFiglia, 1997), and medium spiny neurons (MSN) in the striatum are the primary affected neurons in early-stage HD. Indeed the characteristic pathology in HD patients comprise striatal atrophy and enlargement of the lateral ventricles (Hobbs *et al.*, 2010). As the disease progresses, the loss of neurons extends to other areas, including the deep layer cortical neurons and substantia nigra (Rosas *et al.*, 2006; Tabrizi *et al.*, 2009) and by end stage, typically more than 30% of the brain mass is lost (De La Monte *et al.*, 1988). Therefore, therapeutics targeting HD molecular disease-causing mechanisms, need to effectively distribute to the striatum, and secondarily to other brain areas, in order to achieve a fully effective outcome (Wang *et al.*, 2014). For CNS diseases, the complex brain anatomy and the blood brain barrier (BBB) protection of the brain result in a limited drug distribution which is considered one of the major challenges in the development of treatments for brain diseases. It also has become apparent that results obtained in small animal models often do not translate well to large animals and humans (Eaton and Wishart, 2017).

Three different routes of administration can be used to delivery therapeutics in the brain: intravenous, intrathecal and intraparenchymal (Hocquemiller *et al.*, 2016). Currently,

only the last ensures sufficient delivery of DNA oligonucleotides, siRNAs or gene therapy vectors to deep brain structures such as the striatum. Stereotactic intraparenchymal administration is invasive and cumbersome and the approach would only be suitable for single-dosed approaches with long-term effects such as gene therapeutics (Samaranch *et al.*, 2017). The delivery of various mHTT-lowering RNAi strategies into the striatum, or cerebral ventricles was associated with the reduction of mHTT aggregation and behavioral improvement in HD animal models (Rodriguez-Lebron *et al.*, 2005; DiFiglia *et al.*, 2007; Stanek *et al.*, 2014; Miniarikova *et al.*, 2017; Didiot *et al.*, 2018; Spronck *et al.*, 2019).

The toxicity of misfolded pathogenic proteins and fragments can spread throughout the brain by seeding protein aggregation in recipient cells. Spreading of mHTT between cells is evident from in vitro and animal experiments showing that mHTT aggregate transmission between neurons contributes to HD pathology (Pecho-Vrieseling *et al.*, 2014; Jeon *et al.*, 2016; Ananbeh *et al.*, 2021). One of the mechanisms of intercellular transfer is mediated by the secretion and dissemination of mHTT within extracellular vesicles (EV) (Jeon *et al.*, 2016). EVs are a heterogenous group of nanovesicles, including exosomes and microvesicles, that contain important biological cargos such as cellular miRNAs, long non-coding RNAs, proteins, lipids and DNA (Valadi *et al.*, 2007). Molecular therapies might be able to distribute between affected neuronal cells in the same manner as pathological proteins such as mHTT contributing to improve therapeutic efficacy as disease advances.

HOW GOOD and HOW BAD? – Measuring efficacy and safety of HTT-lowering treatments

In order to assess the therapeutic success of potential treatments it is important to establish a panel of outcomes for both positive and negative effects that are critical for disease progression. Outcomes of efficacy ("how good") include measurements of target engagement, functional improvement and translational biomarkers predictive of the disease advancement (**Figure 3**). For HTT-lowering therapies, on-target lowering efficacy has been assessed in preclinical studies by measuring the reduction of FL-mHTT protein levels and mHTT aggregates within affected CNS regions. For this, numerous in vitro cultures and animal models have been used, including large transgenic models such as HD transgenic minipigs (Baxa *et al.*, 2013; Howland and Munoz-Sanjuan, 2014; Miniarikova *et al.*, 2018). Since brain biopsies are too invasive, it is not feasible to measure lowering efficacy directly in patients' brain. The levels of mHTT (FL-mHTT) in cerebral spinal fluid (CSF) were proposed as markers of on-target efficacy in patients' CNS and have been used in the first clinical trials (Tabrizi *et al.*, 2019). However, it is not clear to which extend the concentrations of mHTT in the CSF reflect the concentrations of mHTT in deep brain areas, or instead and most likely,

they reflect concentrations in spinal cord and cortex, according to the unsuccessful clinical trial with intrathecal infusion of ASOs (Tabrizi *et al.*, 2019). Another biofluid markers commonly used in brain diseases is the concentrations of neurofilament light chain (NfL), a general marker of neuroaxonal damage, in the CSF (Byrne *et al.*, 2018). NfL levels is a good predictor of disease onset, but does not correlated with symptom progression after symptom onset (Byrne *et al.*, 2018; Parkin *et al.*, 2021). Therefore, it is not clear whether it could be a suitable biomarker for response to neuroprotective treatments (Tabrizi *et al.*, 2019). It is important to mention, that although ideal due to their recent contribution in HD pathogenesis, measurements of HTTex1 production or somatic instability in biofluids have not been assessed yet. Measuring these events is challenging since levels are low and first changes mainly take place in striatal neurons.

Other studied biomarkers for early prediction of therapeutic outcomes include volumetric measures by structural magnetic resonance imaging (MRI) (Wilson *et al.*, 2018). In HD patients, striatal volume was identified as the best variable to track longitudinal progression (Abeyasinghe *et al.*, 2021). Hence, monitoring volumetric changes may provide a more reliable measurement of therapeutic improvement. Moreover, imaging motor tracts in thalamus and striatum, first susceptible areas to degeneration, may help to determine timing of treatment and efficacy in pre-manifest patients (Rosas *et al.*, 2006; Zeun *et al.*, 2022).

Safety is a major aspect of drug development, especially for gene targeting therapies which can induce unwanted off-target downregulation of other genes (**Figure 3**). For vector-based gene therapeutics, due to their persistent and irreversible nature, evaluation of long-term HTT-lowering effects as well as potential off-target effects is important (Murlidharan *et al.*, 2014; Keskin *et al.*, 2019). Moreover, pre-existing neutralizing antibodies and AAV-induced immune responses may contribute to treatment durability and patient safety. Most HTT-lowering therapies are non-allele-selective and the potential toxicity of long-term wild-type HTT (wtHTT) lowering is a major safety concern (Kaemmerer and Grondin, 2019). A whole set of preclinical studies, together with first clinical trial, indicates that partial lowering of wtHTT up to a certain extend is well-tolerated for at least 7 months in humanized HD mice (Caron *et al.*, 2020), 6 months in NHP (Grondin *et al.*, 2012) and 4 months in HD patients (Tabrizi *et al.*, 2019)

Figure 3: **Measurements of efficacy ("how good") and safety ("how bad") for HTT-lowering therapies.**

Conclusion

During the last decades, great efforts have led to the development and clinical testing of potential therapeutics for the treatment of HD. However, we are not there yet. Altogether, this mechanistic overview of molecular drivers of HD pathology, current therapeutic modalities and outcomes of efficacy illustrates critical requirements and remaining challenges to achieve therapeutic success. Potentially therapeutic approaches should aim to target the most toxic species in the most affected brain areas. For instance, the reduction of HTTex1 fragments or the suppression of somatic instability, rather than the lowering of full-length mHTT protein alone, are suggested as superior targets to effectively stop disease onset and progression. Next, therapeutic targeting should be preferentially and evenly achieved in earlier and most affected brain areas (i.e striatum) and cells, and secondly in other brain areas in line with disease progression. Finally, development of sensitive indicators of early disease changes are needed to correctly assess these therapies in slow progressing HD patients.

Scope of the thesis

Although HD has a well-defined monogenic cause and promising HTT-lowering therapies are being tested in clinical trials, mechanism of action studies can reveal relevant information about effective targets and outcomes required for successful translation into patients. One of the most advanced HTT lowering therapies for HD is a micro(mi)RNA-based gene therapy which consists of an engineered miRNA targeting the exon 1 sequence of HTT (miHTT) and delivered by adeno-associated virus (AAV) into neuronal striatal cells (AAV-miHTT). AAV-miHTT treatment has previously demonstrated efficacy and safety in reducing mutant HTT protein and rescuing HD phenotype in several HD murine models (Miniarikova *et al.*, 2016, 2017; Spronck *et al.*, 2019; Caron *et al.*, 2020), in transgenic minipigs (Evers *et al.*, 2018) and in HD patient-derived cells (Keskin *et al.*, 2019). However, mechanism of action studies are still limited.

The work in this thesis describes novel mechanistic features of AAV-miHTT treatment for HD, including the targeting of different HTT species, the therapeutic spread between neuronal cells and the development of translational biomarkers to monitor its effect in the affected brain regions.

In **Chapter 2** describes the reduction of highly toxic exon 1 HTT fragments, as well as full-length mutant HTT, in the brain of HD mouse models by AAV-miHTT.

Chapter 3 describes the widespread and sustained lowering efficacy of AAV-miHTT in disease-relevant regions in a large brain in HD transgenic minipigs, and the potential of using biofluids markers to determine vector expression and efficacy in the clinic.

Chapter 4 and **5** describe a novel mechanism of secretion and dissemination of engineered miRNAs mediated by extracellular vesicles (EV). Circulating engineered miRNAs in biofluids were used as sources of pharmacokinetic markers to monitor durability of miRNA therapeutics in the brain of non-human primates. Moreover, the uptake of EV-enriched engineered miRNAs by neighboring cells resulted in gene silencing in recipient cells, indicating therapeutic spread beyond AAV transduction.

Chapter 6 provide a general discussion of the main findings on the thesis and its implications for gene therapies for HD and other neurodegenerative diseases.

In the light of the work of this thesis, we support the reduction of HTTex1 fragment, the persistent efficacy in most affected brain areas, and mechanisms that improve therapeutic spread to all affected cells, as processes that potentially contribute to the successful treatment of HD patients.

References

Abeyasinghe PM, Long JD, Razi A, Pustina D, Paulsen JS, Tabrizi SJ, et al. Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers. Mov Disord 2021; 36: 2282–92.

Alterman JF, Godinho BMDC, Hassler MR, Ferguson CM, Echeverria D, Sapp E, et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat Biotechnol 2019; 37: 884–94.

Ananbeh H, Vodicka P, Kupcova Skalnikova H. Emerging Roles of Exosomes in Huntington's Disease. Int J Mol Sci 2021; 22.

Bachoud-Lévi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, et al. International guidelines for the treatment of Huntington's disease. Front Neurol 2019; 10: 1–18.

Barbaro BA, Lukacsovich T, Agrawal N, Burke J, Bornemann DJ, Purcell JM, et al. Comparative study of naturally occurring Huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease. Hum Mol Genet 2015; 24: 913–25.

Baxa M, Hruska-Plochan M, Juhas S, Vodicka P, Pavlok A, Juhasova J, et al. A transgenic minipig model of Huntington's Disease. J Huntingtons Dis 2013; 2: 47–68.

Bhattacharyya A, Trotta CR, Narasimhan J, Wiedinger KJ, Li W, Effenberger KA, et al. Small molecule splicing modifiers with systemic HTT-lowering activity. Nat Commun 2021 121 2021; 12: 1–12.

Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC, et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. Sci Transl Med 2018; 10.

Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, et al. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res 2020; 48: 36–54.

Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther 2011; 19: 2178–85.

Ciosi M, Maxwell A, Cumming SA, Hensman Moss DJ, Alshammari AM, Flower MD, et al. A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine 2019; 48: 568–80.

Datson NA, González-Barriga A, Kourkouta E, Weij R, Van De Giessen J, Mulders S, et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One 2017; 12

Didiot MC, Ferguson CM, Ly S, Coles AH, Smith AO, Bicknell AA, et al. Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin. Cell Rep 2018; 24: 2553-2560.e5.

DiFiglia M. Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain. Science (80-) 1997; 277: 1990–3.

DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 2007; 104: 17204–9.

Eaton SL, Wishart TM. Bridging the gap: large animal models in neurodegenerative research. Mamm Genome 2017; 28: 324–37.

1

Evers MM, Miniarikova J, Juhas S, Vallès A, Bohuslavova B, Juhasova J, et al. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model. Mol Ther 2018; 26: 2163–77.

Franich NR, Hickey MA, Zhu C, Osborne GF, Ali N, Chu T, et al. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene. J Neurosci Res 2019; 97: 1590–605.

Friedmann T. A brief history of gene therapy. Nat Genet 1992; 2: 93–8.

Garriga-Canut M, Agustín-Pavón C, Herrmann F, Sánchez A, Dierssen M, Fillat C, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A 2012; 109: E3136–45.

Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 2012; 135: 1197–209.

Gu X, Richman J, Langfelder P, Wang N, Zhang S, Bañez-Coronel M, et al. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice. Neuron 2022; 110: 1–20.

Heinz A, Nabariya DK, Krauss S. Huntingtin and Its Role in Mechanisms of RNA-Mediated Toxicity. Toxins (Basel) 2021; 13

Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, Macdonald K, et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010; 31: 1036–41.

Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Hum Gene Ther 2016; 27: 478–96.

Howland DS, Munoz-Sanjuan I. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease. Mov Disord 2014; 29: 1397–403.

Jeon I, Cicchetti F, Cisbani G, Lee S, Li E, Bae J, et al. Human - to - mouse prion - like propagation of mutant huntingtin protein. Acta Neuropathol 2016; 132: 577–92.

Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington's disease: Mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 2017; 7: 1–22.

Kaemmerer WF, Grondin RC. The effects of huntingtin-lowering: what do we know so far? Degener Neurol Neuromuscul Dis 2019; 9: 3.

Keller, CG, Shin, Y, Monteys, AM et al. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat Commun 2022; 13, 1150.

Kennedy L, Evans E, Chen C-M, Craven L, Detloff PJ, Ennis M, et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 2003; 12: 3359–67.

Keskin S, Brouwers CC, Sogorb-Gonzalez M, Martier R, Depla JA, Vallès A, et al. AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes. Mol Ther - Methods Clin Dev 2019; 15: 275–84.

Kingwell K. Double setback for ASO trials in Huntington disease. Nat Rev Drug Discov 2021; 20: 412–3.

Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis. Neuron 2012; 74: 1031–44.

De La Monte SM, Vonsattel JP, Richardson EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988; 47: 516–25.

Leavitt BR, Kordasiewicz HB, Schobel SA. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks. JAMA Neurol 2020; 77: 764–72.

Lee JM, Wheeler VC, Chao MJ, Vonsattel JPG, Pinto RM, Lucente D, et al. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 2015; 162: 516–26.

MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971–83.

Mangiarini L, Sathasivan K, Seller M, Cozens B. Exon1 of the HD gene expanded. Cell 1996; 87: 493–506.

Marxreiter F, Stemick J, Kohl Z. Huntingtin lowering strategies. Int J Mol Sci 2020; 21

McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, et al. Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease. Mol Ther 2011; 19: 2152–62.

Menalled LB, Sison JD, Wu Y, Olivieri M, Li X-J, Li H, et al. Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice. 2002

Miniarikova J, Evers MM, Konstantinova P. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic. Mol Ther 2018; 26: 947–62.

Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, et al. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Mol Ther - Nucleic Acids 2016; 5: e297.

Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease. Gene Ther 2017; 24: 630–9.

Murlidharan G, Samulski RJ, Asokan A. Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci 2014; 7

Neueder A, Dumas AA, Benjamin AC, Bates GP. Regulatory mechanisms of incomplete huntingtin mRNA splicing. Nat Commun 2018; 9

Neueder A, Landles C, Ghosh R, Howland D, Myers RH, Faull RLM, et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. Sci Rep 2017; 7

Papanikolaou E, Bosio A. The Promise and the Hope of Gene Therapy. Front genome Ed 2021; 3

Parkin GM, Corey-Bloom J, Snell C, Castleton J, Thomas EA. Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression. Parkinsonism Relat Disord 2021; 87: 32–8.

Pecho-Vrieseling E, Rieker C, Fuchs S, Bleckmann D, Esposito MS, Botta P, et al. Transneuronal propagation of mutant huntingtin contributes to non–cell autonomous pathology in neurons. Nat Neurosci 2014; 17: 1064–72.

Pfister EL, Chase KO, Sun H, Kennington LA, Conroy F, Johnson E, et al. Safe and Efficient Silencing with a Pol II, but Not a Pol lII, Promoter Expressing an Artificial miRNA Targeting Human Huntingtin. Mol Ther Nucleic Acids 2017; 7: 324–34.

Piguet F, Alves S, Cartier N. Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future. Hum Gene Ther 2017; 28: 988–1003.

Pinto RM, Arning L, Giordano J V., Razghandi P, Andrew MA, Gillis T, et al. Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1. Hum Mol Genet 2020; 29: 2551–67.

Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW, et al. The prevalence of huntington's disease. Neuroepidemiology 2016; 46: 144–53.

Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 2005; 12: 618–33.

Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 2006; 21: 1317–25.

Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014; 10: 204–16.

Roy JCL, Vitalo A, Andrew MA, Mota-Silva E, Kovalenko M, Burch Z, et al. Somatic CAG expansion in Huntington's disease is dependent on the MLH3 endonuclease domain, which can be excluded via splice redirection. Nucleic Acids Res 2021; 49: 3907–18.

Samaranch L, Blits B, San Sebastian W, Hadaczek P, Bringas J, Sudhakar V, et al. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther 2017; 24: 253–61.

Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Housman DE, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. PNAS 2013; 110: 2366–70.

Soares TR, Reis SD, Pinho BR, Duchen MR, Oliveira JMA. Targeting the proteostasis network in Huntington's disease. Ageing Res Rev 2019; 49: 92–103.

Southwell AL, Ko J, Patterson PH. Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease. J Neurosci 2009; 29: 13589–602.

Spronck EA, Brouwers CC, Vallès A, de Haan M, Petry H, van Deventer SJ, et al. AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models. Mol Ther - Methods Clin Dev 2019; 13: 334–43.

Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Ther 2014; 25: 461–74.

Swami M, Hendricks AE, Gillis T, Massood T, Mysore J, Myers RH, et al. Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet 2009; 18: 3039–47.

Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 2020; 16: 529–46.

1

1

Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease. Neuron 2019; 101: 801–19.

Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009; 8: 791–801.

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting Huntingtin Expression in Patients with Huntington's Disease. N Engl J Med 2019; 380: 2307–16.

Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 645–59.

Wang N, Gray M, Lu XH, Cantle JP, Holley SM, Greiner E, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med 2014; 20: 536–41.

Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, et al. Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells. J Biol Chem 2000; 275: 19831–8.

Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol 2017; 16: 837–47.

Wilson H, Dervenoulas G, Politis M. Structural Magnetic Resonance Imaging in Huntington's Disease. Int Rev Neurobiol 2018; 142: 335–80.

Wu T, Yu M, Zhang L, Chen X, Pei Z. I02 Systemic injection of exosomal sirna significantly reduced huntingtin expression in transgenic mice of huntington's disease. J Neurol Neurosurg Psychiatry 2018; 89: A88–9.

Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101: 57–66.

Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease. J Clin Invest 2017; 127

Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease. Nat Med 2019; 25: 1131–42.

Zeun P, McColgan P, Dhollander T, Gregory S, Johnson EB, Papoutsi M, et al. Timing of selective basal ganglia white matter loss in premanifest Huntington's disease. Neuroimage (Amst) 2022; 33: 102927.